All Articles

On May 19, 2020, the FDA approved a new indication for olaparib (Lynparza; AstraZeneca), a PARP inhibitor, for the treatment of men with metastatic castration-resistant prostate cancer and deleterious or suspected deleterious germline or somatic HRR mutation, as determined by an FDA-approved test, whose disease progressed after enzalutamide (Xtandi) or abiraterone acetate (Zytiga) therapy. Olaparib is the first FDA-approved PARP inhibitor for prostate cancer. Read More ›

On May 18, 2020, the FDA approved a new indication for atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, for the first-line treatment of adults with metastatic non–small-cell lung cancer (NSCLC) whose tumor has high PD-L1 expression (PD-L1 stained ≥50% of tumor cells or PD-L1 stained tumor-infiltrating immune cells covering ≥10% of the tumor area), and no EGFR or ALK genomic aberrations, as determined by an FDA-approved test. Read More ›

The federal government is an active participant in shaping and delivering healthcare policy. The panelists in this session addressed the government’s response to COVID-19 and weighed in on some of the issues that their agencies frequently encountered as medical practices grapple with the new normal. Read More ›

Nurses are on the front lines like no other healthcare personnel. In this panel, distinguished nursing professionals discussed topics and issues that have arisen during the pandemic. Led by healthcare educator Lillie D. Shockney, the comprehensive panel covered some of the myriad issues nurse navigators confront now, including rising cancer rates in an aging population, and a decline in numbers of oncology nurses and oncologists. Read More ›

Researchers and clinical investigators are facing a series of unprecedented challenges as they adjust to necessary changes to their work environment resulting from the COVID-19 crisis. In this discussion, moderated by Rob Butcher, CEO, Swim Across America, a panel of researchers discuss the impact of the pandemic on conditions in laboratories, and how graduate students have had to adjust to interruptions in their career trajectories. Read More ›

Employers continue to face significant challenges as they strive to provide healthcare coverage for their employees during the COVID-19 pandemic. In this discussion, moderated by Burt Zweigenhaft, PhD, D.Litt, a panel of experts explore solutions for some of the issues arising in a vastly changed healthcare market, and strategies for improving the way in which health benefits are conceived and implemented. Read More ›

Telehealth continues to play a critical role in providing healthcare services to patients during the COVID-19 pandemic. In a webcast titled COVID-19: Impact on Telehealth, Rick Lee, Executive Chairman, Healthy Platforms and CancerLife, along with a panel of experts, discussed the benefits and ongoing challenges associated with the use of telemedicine and the far-reaching impact of this technology beyond the current crisis. Read More ›

On May 15, 2020, the FDA approved a new indication for the first immunotherapy combination with the PD-1 inhibitor nivolumab (Opdivo; BMS) and the CTLA-4 inhibitor ipilimumab (Yervoy; BMS) as first-line treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and PD-L1 expression of ≥1%, as determined by an FDA-approved test, but without EGFR or ALK genomic alterations. Read More ›

Improvement in progression-free survival observed in the PRIMA clinical trial results in FDA approval of an additional indication for niraparib as first-line maintenance treatment of all patients with advanced ovarian cancer whose disease has had a complete or partial response to first-line platinum-based chemotherapy. Read More ›

According to data from the National Cancer Institute, approximately 1.2% of women in the United States will be diagnosed with ovarian cancer at some point in their lifetime. It is estimated that more than 20,000 women will be diagnosed with ovarian cancer in 2020, and nearly 14,000 women will die from the disease in the same year. Most deaths will occur in women aged >55 years. Read More ›